PATENT CLAIM ANALYSIS

Application Number: 16294615
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["514", "183000"]

Abstract:
The present invention relates to treating, a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIT inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIE inhibitor.

Claim (Index 18):
The method of  claim 17 , wherein the echinomycin is administered at a non-toxic dose.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 1.56757
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13513659', '15234195', '15448737', '14212418', '11632231']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8479009508204954
- 35 USC 102 Novelty (BERT): 0.5852120109699449
- Combined Prediction Score: 0.8216320568354405
- Mean Citation Score: 507.42187200000006
- Max Citation Score: 701.1846
- Similarity Product: 388.3644613345027

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test